Literature DB >> 12125390

[Personality traits of women participating in a breast cancer prevention trial].

Gemma Martino1, Cristina Bellati, Alberto Cola, Gabriella Galperti, Vittorio Krogh, Simona Luci, Milena Raimondi.   

Abstract

We have evaluated the psycho-social factors in women--during menopause with different biological characteristics--who participated in two extensive trials of breast cancer prevention: Diana1 and Tamoxifen. Through the use of a recognized personality test (MMPI, Minnesota Multiphasic Personality Inventory), we observed 500 healthy women who agreed to or refused the health care proposal. The findings show that the women who accept chemical preparations or to modify their dietary habits present different personality traits from those who refuse to adhere. One should ask oneself if the lack of homogeneity of the samples with a different concentration of psycho-social factors can alter the efficacy of a cancer prevention program. During chemoprevention studies, in which a high compliance could bring about a redundancy of experience of sickness, in coherence with our goal of health protection, we think it is necessary to supply psycho-social support which tempers any experience of physical, psychological and inter-personal discomfort in the healthy women. The cognitive model of the personality traits could be programmed also for the compliance of mammographical screening. This model requires the training of health care professionals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12125390

Source DB:  PubMed          Journal:  Epidemiol Prev        ISSN: 1120-9763            Impact factor:   1.901


  1 in total

1.  Factors associated with an individuals' decision to withdraw from genetic counseling for BRCA1 and BRCA2 genes mutations: are personality traits involved?

Authors:  Anita Caruso; Cristina Vigna; Valentina Bigazzi; Carlo Leone; Gabriella Maggi; Aline Martayan; Fabio M Sega; Francesco Cognetti; Antonella Savarese
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.